Onvansertib
NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with an IC50 of 2 nM.
Product Specifications
CAS Number
1034616-18-6
Product Name Alternative
NMS-1286937; NMS-P937
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Polo-like Kinase (PLK)
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/NMS-1286937.html
Purity
99.86
Solubility
DMSO : 21 mg/mL (ultrasonic; warming)
Smiles
O=C(C1=NN(CCO)C2=C1CCC3=CN=C(NC4=CC(N5CCN(C)CC5)=CC=C4OC(F)(F)F)N=C23)N
Molecular Formula
C24H27F3N8O3
Molecular Weight
532.52
Precautions
H302, H315, H319, H335
References & Citations
[1]Beria I, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21 (10) :2969-74.|[2]Valsasina B, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11 (4) :1006-16.|[3]Casolaro A, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8 (3) :e58424.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PLK1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR10394353 96 Well
Sheep Endothelial Nitric Oxide Synthase ELISA kit
Sign In for Pricing
View Details ![1,3-Dihydrobenzo[c]furan](https://cdn.genprice.uk/genprice/uk/genprice2.webp)
MBS1096174-01 0.02 mg (E-Coli)
Recombinant Cyanothece sp. Protein RecA (recA)
Sign In for Pricing
View Details